A. Ascherio, K. Munger, and J. Lunemann, The initiation and prevention of multiple sclerosis, Nature Reviews Neurology, vol.21, issue.11, pp.602-612, 2012.
DOI : 10.1038/nrneurol.2012.198

E. Mowry, L. Krupp, and M. Milazzo, Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis, Ann Neurol, vol.67, pp.618-624, 2010.

T. Runia, W. Hop, and Y. De-rijke, Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis, Neurology, vol.79, issue.3, pp.261-266, 2012.
DOI : 10.1212/WNL.0b013e31825fdec7

S. Simpson, . Jr, B. Taylor, and L. Blizzard, Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis, Ann Neurol, vol.68, pp.193-203, 2010.

E. Mowry, E. Waubant, and C. Mcculloch, Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis, Annals of Neurology, vol.90, issue.2, pp.234-240, 2012.
DOI : 10.1002/ana.23591

M. Soilu-hanninen, J. Aivo, and B. Lindstrom, as an add on treatment to interferon ??-1b in patients with multiple sclerosis, Journal of Neurology, Neurosurgery & Psychiatry, vol.83, issue.5, pp.565-571, 2012.
DOI : 10.1136/jnnp-2011-301876

J. Burton, S. Kimball, and R. Vieth, A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis, Neurology, vol.74, issue.23, pp.1852-1859, 2010.
DOI : 10.1212/WNL.0b013e3181e1cec2

T. Holmoy, A. Lossius, and T. Gundersen, Intrathecal levels of vitamin D and IgG in multiple sclerosis, Acta Neurologica Scandinavica, vol.160, issue.Suppl, pp.28-31, 2012.
DOI : 10.1111/j.1600-0404.2011.01577.x

B. Pozuelo-moyano, J. Benito-leon, and A. Mitchell, A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis, Neuroepidemiology, vol.40, issue.3, pp.147-153, 2013.
DOI : 10.1159/000345122

L. Kappos, C. Polman, and M. Freedman, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006.
DOI : 10.1212/01.wnl.0000237641.33768.8d

L. Kappos, M. Freedman, and C. Polman, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study, The Lancet, vol.370, issue.9585, pp.389-397, 2007.
DOI : 10.1016/S0140-6736(07)61194-5

L. Kappos, M. Freedman, and C. Polman, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, The Lancet Neurology, vol.8, issue.11, pp.987-997, 2009.
DOI : 10.1016/S1474-4422(09)70237-6

A. Ascherio, K. Munger, and R. White, Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression, JAMA Neurology, vol.71, issue.3, pp.306-314, 2014.
DOI : 10.1001/jamaneurol.2013.5993
URL : https://hal.archives-ouvertes.fr/inserm-01103094

M. Hewison, Vitamin D and the Immune System: New Perspectives on an Old Theme, Endocrinology and Metabolism Clinics of North America, vol.39, issue.2, pp.365-379, 2010.
DOI : 10.1016/j.ecl.2010.02.010

P. Brex, O. Ciccarelli, O. Riordan, and J. , A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis, New England Journal of Medicine, vol.346, issue.3, pp.158-164, 2002.
DOI : 10.1056/NEJMoa011341

G. Nagtegaal, C. Pohl, and M. Wattjes, Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome, Multiple Sclerosis Journal, vol.19, issue.2, pp.234-242, 2014.
DOI : 10.1001/archneur.61.2.217
URL : https://hal.archives-ouvertes.fr/inserm-01103080

R. Irizarry, B. Bolstad, and F. Collin, Summaries of Affymetrix GeneChip probe level data, Nucleic Acids Research, vol.31, issue.4, p.15, 2003.
DOI : 10.1093/nar/gng015

B. Bolstad, R. Irizarry, and M. Astrand, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, vol.19, issue.2, pp.185-193, 2003.
DOI : 10.1093/bioinformatics/19.2.185

M. Dai, P. Wang, and A. Boyd, Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data, Nucleic Acids Research, vol.33, issue.20, p.175, 2005.
DOI : 10.1093/nar/gni179

Y. Benjamini and Y. Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, J R Stat Soc, vol.51, pp.289-300, 1995.

A. Subramanian, P. Tamayo, and V. Mootha, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles, Proceedings of the National Academy of Sciences, vol.102, issue.43, pp.15545-15550, 2005.
DOI : 10.1073/pnas.0506580102

S. Heikkinen, S. Vaisanen, and P. Pehkonen, Nuclear hormone 1??,25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy, Nucleic Acids Research, vol.39, issue.21, pp.9181-9193, 2011.
DOI : 10.1093/nar/gkr654

S. Ramagopalan, A. Heger, and A. Berlanga, A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution, Genome Research, vol.20, issue.10, pp.1352-1360, 2010.
DOI : 10.1101/gr.107920.110

G. Dennis, . Jr, B. Sherman, and D. Hosack, Database for Annotation, Visualization, and Integrated Discovery, Genome Biology, vol.4, issue.5, p.3, 2003.
DOI : 10.1186/gb-2003-4-5-p3

T. Bailey, M. Boden, and F. Buske, MEME SUITE: tools for motif discovery and searching, Nucleic Acids Research, vol.37, issue.Web Server, pp.202-208, 2009.
DOI : 10.1093/nar/gkp335

J. Bryne, E. Valen, and M. Tang, JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update, Nucleic Acids Research, vol.36, issue.Database, pp.102-106, 2008.
DOI : 10.1093/nar/gkm955

D. Levy, D. Kessler, and R. Pine, Interferon-induced nuclear factors that bind a shared promoter element correlate with positive and negative transcriptional control., Genes & Development, vol.2, issue.4, pp.383-393, 1988.
DOI : 10.1101/gad.2.4.383

O. Aktas, P. Kury, and B. Kieseier, Fingolimod is a potential novel therapy for multiple sclerosis, Nature Reviews Neurology, vol.158, issue.7, pp.373-382, 2010.
DOI : 10.1038/nrneurol.2010.76

M. Mehling, T. Johnson, and J. Antel, Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis, Neurology, vol.76, issue.Issue 8, Supplement 3, pp.20-27, 2011.
DOI : 10.1212/WNL.0b013e31820db341

A. Handel, G. Sandve, and G. Disanto, Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease, BMC Medicine, vol.22, issue.1, p.163, 2013.
DOI : 10.1093/emboj/cdg147

A. Norman, Vitamin D Receptor: New Assignments for an Already Busy Receptor, Endocrinology, vol.147, issue.12, pp.5542-5548, 2006.
DOI : 10.1210/en.2006-0946

A. Norman, A vitamin D nutritional cornucopia: new insights concerning the serum 25-hydroxyvitamin D status of the US population, American Journal of Clinical Nutrition, vol.88, issue.6, pp.1455-1456, 2008.
DOI : 10.3945/ajcn.2008.27049

P. Stambolsky, Y. Tabach, and G. Fontemaggi, Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53, Cancer Cell, vol.17, issue.3, pp.273-285, 2010.
DOI : 10.1016/j.ccr.2009.11.025

M. Holick, Vitamin D Deficiency, New England Journal of Medicine, vol.357, issue.3, pp.266-281, 2007.
DOI : 10.1056/NEJMra070553

B. Institute, Gene set enrichment analysis: GSEA user guide Available at http://www.broadinstitute.org/gsea, GSEAUserGuide.pdf. Accessed, vol.1, 2014.

A. Franceschini, D. Szklarczyk, and S. Frankild, STRING v9.1: protein-protein interaction networks, with increased coverage and integration, Nucleic Acids Research, vol.41, issue.D1, pp.808-815, 2013.
DOI : 10.1093/nar/gks1094

D. Legrand, This article is part of Special Issue entitled Lactoferrin and has undergone the Journal???s usual peer review process., Biochemistry and Cell Biology, vol.90, issue.3, pp.252-268, 2012.
DOI : 10.1139/o11-056

D. Auer, E. Schumann, and T. Kumpfel, Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis, Annals of Neurology, vol.44, issue.2, pp.276-277, 2000.
DOI : 10.1002/1531-8249(200002)47:2<276::AID-ANA28>3.0.CO;2-1

J. Killestein, M. Rep, and J. Meilof, Seasonal variation in immune measurements and MRI markers of disease activity in MS, Neurology, vol.58, issue.7, pp.1077-1080, 2002.
DOI : 10.1212/WNL.58.7.1077

M. Rovaris, G. Comi, and M. Sormani, Effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis, Annals of Neurology, vol.49, issue.3, pp.415-416, 2001.
DOI : 10.1002/ana.83

J. Smolders, M. Thewissen, and R. Theunissen, Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis, Journal of Neuroimmunology, vol.235, issue.1-2, pp.91-97, 2011.
DOI : 10.1016/j.jneuroim.2011.03.012

J. Smolders, K. Schuurman, and M. Van-strien, Expression of Vitamin D Receptor and Metabolizing Enzymes in Multiple Sclerosis???Affected Brain Tissue, Journal of Neuropathology & Experimental Neurology, vol.72, issue.2, pp.91-105, 2013.
DOI : 10.1097/NEN.0b013e31827f4fcc

M. Comabella, J. Lunemann, and J. Rio, A type I interferon signature in monocytes is associated with poor response to interferon-?? in multiple sclerosis, Brain, vol.132, issue.12, pp.3353-3365, 2009.
DOI : 10.1093/brain/awp228

K. Gandhi, F. Mckay, and M. Cox, The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis, Human Molecular Genetics, vol.19, issue.11, pp.2134-2143, 2010.
DOI : 10.1093/hmg/ddq090

D. Nickles, H. Chen, and M. Li, Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls, Human Molecular Genetics, vol.22, issue.20, pp.4194-4205, 2013.
DOI : 10.1093/hmg/ddt267

L. Van-baarsen, T. Van-der-pouw-kraan, and J. Kragt, A subtype of multiple sclerosis defined by an activated immune defense program, Genes and Immunity, vol.34, issue.6, pp.522-531, 2006.
DOI : 10.1038/sj.gene.6364324

G. Comi, M. Filippi, and F. Barkhof, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study, The Lancet, vol.357, issue.9268, pp.1576-1582, 2001.
DOI : 10.1016/S0140-6736(00)04725-5

E. Croze, K. Yamaguchi, and V. Knappertz, Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis, The Pharmacogenomics Journal, vol.11, issue.5, pp.443-451, 2013.
DOI : 10.2165/11204560-000000000-00000

L. Van-baarsen, S. Vosslamber, and M. Tijssen, Pharmacogenomics of Interferon-?? Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients, PLoS ONE, vol.60, issue.4, p.1927, 2008.
DOI : 10.1371/journal.pone.0001927.s001

J. Satoh and H. Tabunoki, Molecular network of chromatin immunoprecipitation followed by deep sequencing-based vitamin D receptor target genes, Multiple Sclerosis Journal, vol.32, issue.8, pp.1035-1045, 2013.
DOI : 10.4049/jimmunol.173.5.2909

E. Costa, M. Hirst, and D. Feldman, Regulation of 1,25-Dihydroxyvitamin D3 Receptors by Vitamin D Analogs in Cultured Mammalian Cells*, Endocrinology, vol.117, issue.5, pp.2203-2210, 1985.
DOI : 10.1210/endo-117-5-2203

D. Prosser and G. Jones, Enzymes involved in the activation and inactivation of vitamin D, Trends in Biochemical Sciences, vol.29, issue.12, pp.664-673, 2004.
DOI : 10.1016/j.tibs.2004.10.005

C. Zierold, H. Darwish, and H. Deluca, Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter, J Biol Chem, vol.270, pp.1675-1678, 1995.